[Clinical trial of the monoclonal antibody drug mabthera (Rituximab) in the treatment of non-Hodgkin lymphoma].
Mabthera has been tested for its influence on relapsing and refractory low-grade non-Hodgkin's lymphoma in a comparative study using monotherapy (R) or in conjunction with CHOP (R-CHOP) chemotherapy. Out of 33 in-patients, effect was evaluated in 31 (rituximab monotherapy--16, R-CHOP--31). MabThera monochemotherapy proved effective in 62% of those who had received several other regimes, R-CHOP-74%. Both regimens were followed by long (ca.12 months) stable remissions. No difference in complete and partial remission duration was reported, whereas complete remission ranged 6-13 months, partial--2-24 months. Clinically significant results were 87.5% in the monotherapy group, and 87%--R-CHOP. No correlation was found between the efficacy of both regimens, on the one hand, and morphological patterns of lymphoma, on the other. CHOP chemotherapy had been given to 7 out of 15 patients treated with R-CHOP. Four of them had partial remission thus suggesting a modulating effect of rituximab on the resistance of previous treatment. R-CHOP was well tolerated by all patients, irrespective of age, did not contribute to untoward side-effects and assured longer remission.
Korolenko
V O
VO
N.N. Petrov Research Institute of Oncology, Ministry of Health of the RF, St. Petersburg.
Gershanovich
M L
ML
Leenman
E E
EE
Tikhonova
V V
VV
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D011241:Prednisone / Q000008:administration & dosage; D012074:Remission Induction; D000069283:Rituximab; D013997:Time Factors; D016896:Treatment Outcome; D014750:Vincristine / Q000008:administration & dosage
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone